| Press releases

Focus magazine lists Formycon as growth champion 2017

Formycon has been named “growth champion 2017” in the category “Chemistry and Pharma” by the news magazine Focus. In the overall ranking, Formycon took second place.


Munich Capital Market Conference

December 7, 2016; Munich/Germany

Financial reports

Half-Year Report 2016

Published on 20. September 2016

  • Forschungssiegel_Teaser_Webseite-en
  • buchner_en
  • pipeline-en-teaser
  • Foto_MedicineMaker_Powerlist
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.